NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Subscribe To Our Newsletter & Stay Updated